St Andrews Research Repository

St Andrews University Home
View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Perspective for precision medicine for tuberculosis

Thumbnail
View/Open
Lange_2020_Frontiers_perspectiveprecision_VoR_CCBY.pdf (579.0Kb)
Date
08/10/2020
Author
Lange, Christoph
Aarnoutse, Rob
Chesov, Dumitru
van Crevel, Reinout
Gillespie, Stephen H.
Grobbel, Hans-Peter
Kalsdorf, Barbara
Kontsevaya, Irina
van Laarhoven, Arjan
Nishiguchi, Tomoki
Mandalakas, Anna
Merker, Matthias
Niemann, Stefan
Köhler, Niklas
Heyckendorf, Jan
Reimann, Maja
Ruhwald, Morten
Sanchez-Carballo, Patricia
Schwudke, Dominik
Waldow, Franziska
DiNardo, Andrew R.
Keywords
Precision medicine
Tuberculosis
Tailor-made regimen
Mycobacterial genotypes
Endotypes
QR180 Immunology
RM Therapeutics. Pharmacology
Metadata
Show full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Abstract
Tuberculosis is a bacterial infectious disease that is mainly transmitted from human to human via infectious aerosols. Currently, tuberculosis is the leading cause of death by an infectious disease world-wide. In the past decade, the number of patients affected by tuberculosis has increased by ~20 percent and the emergence of drug-resistant strains of Mycobacterium tuberculosis challenges the goal of elimination of tuberculosis in the near future. For the last 50 years, management of patients with tuberculosis has followed a standardized management approach. This standardization neglects the variation in human susceptibility to infection, immune response, the pharmacokinetics of drugs, and the individual duration of treatment needed to achieve relapse-free cure. Here we propose a package of precision medicine-guided therapies that has the prospect to drive clinical management decisions, based on both host immunity and M. tuberculosis strains genetics. Recently, important scientific discoveries and technological advances have been achieved that provide a perspective for individualized rather than standardized management of patients with tuberculosis. For the individual selection of best medicines and host-directed therapies, personalized drug dosing, and treatment durations, physicians treating patients with tuberculosis will be able to rely on these advances in systems biology and to apply them at the bedside.
Citation
Lange , C , Aarnoutse , R , Chesov , D , van Crevel , R , Gillespie , S H , Grobbel , H-P , Kalsdorf , B , Kontsevaya , I , van Laarhoven , A , Nishiguchi , T , Mandalakas , A , Merker , M , Niemann , S , Köhler , N , Heyckendorf , J , Reimann , M , Ruhwald , M , Sanchez-Carballo , P , Schwudke , D , Waldow , F & DiNardo , A R 2020 , ' Perspective for precision medicine for tuberculosis ' , Frontiers in Immunology , vol. 11 , 566608 . https://doi.org/10.3389/fimmu.2020.566608
Publication
Frontiers in Immunology
Status
Peer reviewed
DOI
https://doi.org/10.3389/fimmu.2020.566608
ISSN
1664-3224
Type
Journal item
Rights
Copyright © 2020 Lange, Aarnoutse, Chesov, van Crevel, Gillespie, Grobbel, Kalsdorf, Kontsevaya, van Laarhoven, Nishiguchi, Mandalakas, Merker, Niemann, Köhler, Heyckendorf, Reimann, Ruhwald, Sanchez-Carballo, Schwudke, Waldow and DiNardo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Description
Funding: German Center for Infection Research (DZIF) Clinical TB TTU-TB 02.704. The publication of this article was supported by the Open Access Publication Fund of the Leibniz Association.
Collections
  • University of St Andrews Research
URI
http://hdl.handle.net/10023/20756

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

Accessibility

Read our Accessibility statement.

How to submit research papers

The full text of research papers can be submitted to the repository via Pure, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter